These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 28468980)

  • 1. Identification of Protective B-Cell Epitopes within the Novel Malaria Vaccine Candidate Plasmodium falciparum Schizont Egress Antigen 1.
    Nixon CE; Park S; Pond-Tor S; Raj D; Lambert LE; Orr-Gonzalez S; Barnafo EK; Rausch KM; Friedman JF; Fried M; Duffy PE; Kurtis JD
    Clin Vaccine Immunol; 2017 Jul; 24(7):. PubMed ID: 28468980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maternally-derived Antibodies to Schizont Egress Antigen-1 and Protection of Infants From Severe Malaria.
    Kurtis JD; Raj DK; Michelow IC; Park S; Nixon CE; McDonald EA; Nixon CP; Pond-Tor S; Jha A; Taliano RJ; Kabyemela ER; Friedman JF; Duffy PE; Fried M
    Clin Infect Dis; 2019 May; 68(10):1718-1724. PubMed ID: 30165569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibodies to PfSEA-1 block parasite egress from RBCs and protect against malaria infection.
    Raj DK; Nixon CP; Nixon CE; Dvorin JD; DiPetrillo CG; Pond-Tor S; Wu HW; Jolly G; Pischel L; Lu A; Michelow IC; Cheng L; Conteh S; McDonald EA; Absalon S; Holte SE; Friedman JF; Fried M; Duffy PE; Kurtis JD
    Science; 2014 May; 344(6186):871-7. PubMed ID: 24855263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of maternally derived antibodies to Plasmodium falciparum Schizont Egress Antigen-1 on the endogenous production of anti-PfSEA-1 in offspring.
    Park S; Nixon CE; Pond-Tor S; Kabyemela ER; Fried M; Duffy PE; Kurtis JD; Friedman JF
    Vaccine; 2019 Aug; 37(35):5044-5050. PubMed ID: 31288996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An evolutionary approach to identify potentially protective B cell epitopes involved in naturally acquired immunity to malaria and the role of EBA-175 in protection amongst denizens of Bolifamba, Cameroon.
    Nyasa RB; Kimbi HK; Zofou D; DeBarry JD; Kissinger JC; Titanji VP
    Malar J; 2016 May; 15(1):281. PubMed ID: 27207101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longitudinal study of natural immune responses to the Plasmodium falciparum apical membrane antigen (AMA-1) in a holoendemic region of malaria in western Kenya: Asembo Bay Cohort Project VIII.
    Udhayakumar V; Kariuki S; Kolczack M; Girma M; Roberts JM; Oloo AJ; Nahlen BL; Lal AA
    Am J Trop Med Hyg; 2001 Aug; 65(2):100-7. PubMed ID: 11508382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human antibodies to recombinant protein constructs of Plasmodium falciparum Apical Membrane Antigen 1 (AMA1) and their associations with protection from malaria.
    Polley SD; Mwangi T; Kocken CH; Thomas AW; Dutta S; Lanar DE; Remarque E; Ross A; Williams TN; Mwambingu G; Lowe B; Conway DJ; Marsh K
    Vaccine; 2004 Dec; 23(5):718-28. PubMed ID: 15542195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Naturally acquired antibody responses to Plasmodium falciparum merozoite surface protein 4 in a population living in an area of endemicity in Vietnam.
    Wang L; Richie TL; Stowers A; Nhan DH; Coppel RL
    Infect Immun; 2001 Jul; 69(7):4390-7. PubMed ID: 11401978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epitope Mapping and Fine Specificity of Human T and B Cell Responses for Novel Candidate Blood-Stage Malaria Vaccine P27A.
    Geiger KM; Guignard D; Yang C; Bikorimana JP; Correia BE; Houard S; Mkindi C; Daubenberger CA; Spertini F; Corradin G; Audran R
    Front Immunol; 2020; 11():412. PubMed ID: 32210975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced acquired antibodies to a chimeric Plasmodium falciparum antigen; UB05-09 is associated with protective immunity against malaria.
    Dinga JN; Gamua SD; Titanji VPK
    Parasite Immunol; 2017 Aug; 39(8):. PubMed ID: 28543553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A linear peptide containing minimal T- and B-cell epitopes of Plasmodium falciparum circumsporozoite protein elicits protection against transgenic sporozoite challenge.
    Calvo-Calle JM; Oliveira GA; Watta CO; Soverow J; Parra-Lopez C; Nardin EH
    Infect Immun; 2006 Dec; 74(12):6929-39. PubMed ID: 17030584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between naturally acquired antibodies to erythrocyte-binding antigens of Plasmodium falciparum and protection from malaria and high-density parasitemia.
    Richards JS; Stanisic DI; Fowkes FJ; Tavul L; Dabod E; Thompson JK; Kumar S; Chitnis CE; Narum DL; Michon P; Siba PM; Cowman AF; Mueller I; Beeson JG
    Clin Infect Dis; 2010 Oct; 51(8):e50-60. PubMed ID: 20843207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group.
    Stoute JA; Slaoui M; Heppner DG; Momin P; Kester KE; Desmons P; Wellde BT; Garçon N; Krzych U; Marchand M
    N Engl J Med; 1997 Jan; 336(2):86-91. PubMed ID: 8988885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasmodium falciparum Protein Microarray Antibody Profiles Correlate With Protection From Symptomatic Malaria in Kenya.
    Dent AE; Nakajima R; Liang L; Baum E; Moormann AM; Sumba PO; Vulule J; Babineau D; Randall A; Davies DH; Felgner PL; Kazura JW
    J Infect Dis; 2015 Nov; 212(9):1429-38. PubMed ID: 25883384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity of a chimeric Plasmodium falciparum merozoite surface protein vaccine in Aotus monkeys.
    Burns JM; Miura K; Sullivan J; Long CA; Barnwell JW
    Malar J; 2016 Mar; 15():159. PubMed ID: 26975721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody-mediated growth inhibition of Plasmodium falciparum: relationship to age and protection from parasitemia in Kenyan children and adults.
    Dent AE; Bergmann-Leitner ES; Wilson DW; Tisch DJ; Kimmel R; Vulule J; Sumba PO; Beeson JG; Angov E; Moormann AM; Kazura JW
    PLoS One; 2008; 3(10):e3557. PubMed ID: 18958285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequential Phase 1 and Phase 2 randomized, controlled trials of the safety, immunogenicity and efficacy of combined pre-erythrocytic vaccine antigens RTS,S and TRAP formulated with AS02 Adjuvant System in healthy, malaria naïve adults.
    Kester KE; Gray Heppner D; Moris P; Ofori-Anyinam O; Krzych U; Tornieporth N; McKinney D; Delchambre M; Ockenhouse CF; Voss G; Holland C; Beckey JP; Ballou WR; Cohen J;
    Vaccine; 2014 Nov; 32(49):6683-91. PubMed ID: 24950358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of naturally acquired IgG antibodies against Plasmodium falciparum serine repeat antigen-5 with reduced placental parasitemia and normal birth weight in pregnant Ugandan women: a pilot study.
    Owalla TJ; Palacpac NM; Shirai H; Horii T; Egwang TG
    Parasitol Int; 2013 Jun; 62(3):237-9. PubMed ID: 23395684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody profiles to wheat germ cell-free system synthesized Plasmodium falciparum proteins correlate with protection from symptomatic malaria in Uganda.
    Kanoi BN; Takashima E; Morita M; White MT; Palacpac NM; Ntege EH; Balikagala B; Yeka A; Egwang TG; Horii T; Tsuboi T
    Vaccine; 2017 Feb; 35(6):873-881. PubMed ID: 28089547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strain-transcending immune response generated by chimeras of the malaria vaccine candidate merozoite surface protein 2.
    Krishnarjuna B; Andrew D; MacRaild CA; Morales RA; Beeson JG; Anders RF; Richards JS; Norton RS
    Sci Rep; 2016 Feb; 6():20613. PubMed ID: 26865062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.